<i>In vivo</i> microdialysis with ultra performance liquid chromatography–mass spectrometry for analysis of tetramethylpyrazine and its interaction with borneol in rat brain and blood

Liao, Weiguo; Huang, Xiaojie; Yin, Yilong; Liu, Bin; Zhu, Runzhi

doi:10.1002/bmc.4210

Cited by 9 publications

(6 citation statements)

References 41 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BO can act as an effective adjuvant for delivering TMP to the brain. Studies have shown that the co-administration of BO could significantly increase oral absorption, areas under the concentration-time curve (AUC), and the concentration of TMP in the brain tissue ( Yan-Yu et al, 2007 ; Liao et al, 2018 ; Wu et al, 2018 ).…”

Section: Drug Delivery System Of Tetramethylpyrazinementioning

confidence: 99%

Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review

et al. 2022

View full text Add to dashboard Cite

Central nervous system (CNS) diseases can lead to motor, sensory, speech, cognitive dysfunction, and sometimes even death. These diseases are recognized to cause a substantial socio-economic impact on a global scale. Tetramethylpyrazine (TMP) is one of the main active ingredients extracted from the Chinese herbal medicine Ligusticum striatum DC. (Chuan Xiong). Many in vivo and in vitro studies have demonstrated that TMP has a certain role in the treatment of CNS diseases through inhibiting calcium ion overload and glutamate excitotoxicity, anti-oxidative/nitrification stress, mitigating inflammatory response, anti-apoptosis, protecting the integrity of the blood-brain barrier (BBB) and facilitating synaptic plasticity. In this review, we summarize the roles and mechanisms of action of TMP on ischemic cerebrovascular disease, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, cognitive impairments, migraine, and depression. Our review will provide new insights into the clinical applications of TMP and the development of novel therapeutics.

show abstract

Section: Drug Delivery System Of Tetramethylpyrazinementioning

confidence: 99%

Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The brain tissue was homogenated with isotonic buffer solution (pH 7.4) and centrifuge at 10,000 rpm2-4°C, the supernatant was collected in an Eppendorf tube. 100 µl of brain homogenate was mixed with 300 µl of methanol and further centrifuged at 10,000 rpm; 2-4°C, the supernatant was collected and stored in -20°C for HPLC analysis (Wang et al 2011;Feng et al 2017;Liao et al 2018).…”

Section: Plasma/brain Sample Preparationmentioning

confidence: 99%

Combination Therapy for Cerebral Ischemia: Do Progesterone and Noscapine Provide Better Neuroprotection Than Either Alone in the Treatment ?

Kawadkar¹,

Mandloi²,

Singh³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: Ischemic stroke presents multifaceted pathological outcomes with overlapping mechanisms of cerebral injury. High mortality and disability with stroke warrant a novel multi-targeted therapeutic approach. The neuroprotection with progesterone (PG) and noscapine (NOS) on cerebral ischemia-reperfusion (I-R) injury was demonstrated individually, but the outcome of combination treatment to alleviate cerebral damage is still unexplored.Methods: Randomly divided groups of rats (n=6) were Sham-operated, I-R, PG (8mg/kg), NOS (10mg/kg), and PG+NOS (8mg/kg+10mg/kg). The rats exposed to bilateral common carotid artery occlusion, except Sham-operated to investigate the therapeutic outcome of PG and NOS alone and in combination on I-R injury. Besides the alterations in cognitive and motor abilities, we estimated infarct area, oxidative stress, blood-brain barrier (BBB) permeability, and histology after treatment. Pharmacokinetic parameters like Cmax, Tmax, half-life, and AUC0-t were estimated in biological samples to substantiate the therapeutic outcomes of the combination treatment.Results: We report PG and NOS prevent loss of motor ability and improved spatial memory after cerebral I-R injury. Combination treatment significantly reduced inflammation and restricted infarction; it attenuated oxidative stress, BBB damage, and improved grip strength. Histopathological analysis demonstrated a significant reduction in leukocyte infiltration with the most profound effect in the combination group. Simultaneous analysis of PG and NOS in plasma revealed enhanced peak drug concentration, improved AUC, and prolonged half-life; the drug levels in the brain have increased significantly for both. Conclusion: We conclude that PG and NOS have beneficial effects against brain damage and, the co-administration further reinforced neuroprotection in the cerebral ischemia-reperfusion injury.

show abstract

“…It can enhance the permeability of various membranes, including gastrointestinal mucosa and skin, and even blood-brain barrier [14][15][16][17][18]. Borneol can promote the absorption of Ligustrazine and increase blood flow during ischemia [19]. In the process of studying the pharmacokinetic characteristics of borneol modified tanshinone IIA liposomes in rats, ye x et al found that borneol modified liposomes could significantly increase the maximum plasma concentration and area under the curve of tanshinone IIA during cerebral ischemia-reperfusion [20].…”

Section: Introductionmentioning

confidence: 99%

Effects of Borneol on Apoptosis in Hypoxia/Reoxygenation H9C2 Rat Cardiomyocytes

Zhang

Wen

Zhang

et al. 2022

Preprint

View full text Add to dashboard Cite

Effective therapies to reduce ischemia/reperfusion and hypoxia/reoxygenation injury are currently lacking. Borneol has a clear protective effect on ischemia-reperfusion injury, and its protective effect on myocardial hypoxia/reoxygenation and its mechanism have remained to be elucidated. This study investigated the protective effects of borneol on H9C2 cardiomyocytes during hypoxia/reoxygenation injury and to explore the underlying molecular mechanisms. H9C2 rat cardiomyocytes were cultured, the MIRI model was established by hypoxia for 5h and reoxygenation for 24h. The cells were divided into control group, hypoxia/reoxygenation group (H/R group), (low-, medium-, high-) dose borneol group. Borneol administration groups were pre-treated for 12h with different doses of borneol prior to hypoxia/reoxygenation, 24h after reoxygenation, the cells or culture medium were collected for testing. The results showed that borneol has no cytotoxicity and can enhance the viability of cardiomyocytes, significantly increased the SOD content, significantly decreased LDH leakage in cell culture medium, and reduced evidently the apoptosis rate, down-regulated the expression of Bax and Caspase-3. In conclusion, this study demonstrated that borneol has a definite protective effect on hypoxia/reoxygenation-induced injury of rat cardiomyocytes, and its protective mechanism can be related to the inhibition of apoptosis by reducing the expression of Bax and Caspase-3.

show abstract

In vivo microdialysis with ultra performance liquid chromatography–mass spectrometry for analysis of tetramethylpyrazine and its interaction with borneol in rat brain and blood

Cited by 9 publications

References 41 publications

Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review

Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review

Combination Therapy for Cerebral Ischemia: Do Progesterone and Noscapine Provide Better Neuroprotection Than Either Alone in the Treatment ?

Effects of Borneol on Apoptosis in Hypoxia/Reoxygenation H9C2 Rat Cardiomyocytes

Contact Info

Product

Resources

About